$0.388
-0.005 (-1.17%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
ENSC Prediction & Forecast by Similar Chart Analysis
Alphio's ENSC stock price prediction model matches the current Ensysce Biosciences Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.38 (-1.43%). The 1-week path is $0.38 (-1.66%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Ensysce Biosciences Inc Stock?
Ensysce Biosciences Inc is a good buy right now due to its recent acquisition of Cy Biopharma and securing $77 million in financing, which has positively impacted its stock price, increasing by 44.83% to $0.52. Additionally, the stock has shown a 58.06% increase over the last 20 days, indicating strong momentum. However, the company has a high risk with a current debt to equity ratio of 0%, suggesting potential financial instability if revenues do not improve.
ENSC stock price ended at $0.39 on Tuesday, after losing -1.17%
Ensysce Biosciences Inc (ENSC) last closed at $0.3881, losing -1.17%. These facts feed the 1-day and 1-week ENSC price prediction above.
Forecast Drivers
Ensysce Biosciences Inc (ENSC) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches ENSC, ranked by similarity.
Seasonality analysis for ENSC
Historically the probability of a positive September return for ENSC is 0.00%. January offers the highest probability of a positive month at 42.62%, while March is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.